Apricus Biosciences Inc news

   Watch this stock
Showing stories 1 - 10 of about 83   

Articles published

APRI 2.20 -0.14 (-5.98%)
price chart
Apricus Biosciences And Vitaros: Update On The Launch (APRI)
It's been almost six months since Vitaros was first launched by Apricus Biosciences (NASDAQ:APRI) in the UK, with follow-up launches in Germany, Sweden and Belgium.
Related articles »  
Apricus Biosciences Announces Issuance of U.S. Patent for RayVa(TM)
SAN DIEGO, Jan. 27, 2015 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, announced that today, January 27, 2015, the United States Patent and ...
RayVa Patent Award Sends Apricus Biosciences Inc (APRI) Stock Trading Up  Bidness ETC
Apricus Bio up on issuance of patent (APRI)  Seeking Alpha (registration)
Taglich Brothers Rating Update on Apricus Biosciences Inc
Apricus Biosciences Inc (NASDAQ:APRI) has posted gains of 6.7% or 0.13 points. After opening at $1.91, the shares hit an intraday high of $2.16 and an intraday low of $1.91, before closing the session at $2.07.
Apricus Biosciences Announces $11 Million Registered Direct Offering With ...
SAN DIEGO, Feb. 11, 2015 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced that it has entered into definitive agreements with ...
Apricus closes direct equity offering (APRI)  Seeking Alpha (registration)
Analyst Rating Update on Apricus Biosciences Inc
Apricus Biosciences Inc (NASDAQ:APRI) has received a short term rating of hold from research analysts at Zacks with a rank of 3. The company has been rated an average of 1.33 by 3 Wall Street Analysts.
Investors Alert: Apricus Biosciences (NASDAQ:APRI), Marine Petroleum Trust ...  Gaining Green
Stocks Buzz: AOL Inc. (NYSE:AOL), Ariad Pharmaceuticals Inc. (NASDAQ:ARIA ...  Property Mentor
Apricus Biosciences: A Screaming Buy Or A Falling Knife?
Apricus Biosciences, Inc. (NASDAQ:APRI) recently began their launch of Vitaros, a topical treatment for Erectile Dysfunction (NYSE:ED), with availability in the UK, Sweden, and now Germany.
Apricus Biosciences to Present at Biotech Showcase 2015
SAN DIEGO, Jan. 6, 2015 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced Richard Pascoe, Chief Executive Officer, will present ...
Related articles »  
Apricus Biosciences Expands Exclusive License Agreement With an Existing ...
SAN DIEGO, Feb. 3, 2015 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced that it has further expanded its exclusive license ...
Apricus Biosciences (APRI) Gains After Announcing Expanded License ...  StreetInsider.com
Apricus Biosciences to Present at the 17th Annual BIO CEO & Investor ...  Nasdaq
Apricus Biosciences Inc Short Interest Climbs by 4%
Apricus Biosciences Inc (NASDAQ:APRI), In a major negative the short interest in Apricus Biosciences, Inc shot up by 4% or 89,532 shares.
Apricus Biosciences Appoints Brian T. Dorsey as Chief Development Officer
SAN DIEGO, Dec. 2, 2014 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced the appointment of Brian T. Dorsey as the Company's ...
Related articles »